The study uses the BD Libertas wearable injector for the subcutaneous delivery of complex biologics. The company said it represents a significant advancement in accelerating innovation in drug-device combination products. It could provide greater flexibility for patients, including potential conversion from infused medications that require patients to travel to a hospital or clinic to more convenient patient care in various settings, including self-injection at home.
BD said the selection of Libertas follows successful outcomes from more than 50 BD conducted pre-clinical and clinical studies. Those include a device clinical study in which 100% of participants stated they would like to use Libertas if prescribed.
Libertas, a prefilled, ready-to-use drug delivery system delivers complex biologics through subcutaneous injection. It offers a customizable, patient-centric solution for high-viscosity biologics and a range of therapies. The company offers it in 2-5 mL and 5-10 mL configurations providing flexibility for diverse therapeutic requirements.
The device features a fully mechanical, patient ready-to-use design with a simple peel, stick and click mechanism. It requires no end-user filling or assembly.
“This trial demonstrates BD’s commitment to helping pharma companies by advancing large-volume injection science, ensuring therapies are accessible and patient friendly by offering more efficient and convenient options for biologics,” said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. “BD’s enhanced testing capabilities acquired through ZebraSci and the proven capabilities of the BD Libertas Wearable Injector technology further position BD as an innovative leader in drug delivery.”
